癌症相关突变对多 (ADP-ribose) 聚合酶1抑制的影响
Neel Shanmugam1, Shubham Chatterjee2, G Andrés Cisneros2,3
1Department of Chemistry, University of North Texas, Denton, Texas 76201, United States.
The journal of physical chemistry. B
|February 18, 2025
概括
在Poly (ADP-ribose) 聚合酶1 (PARP1) 中的V762A突变会影响其与癌症药物的相互作用. 塔拉佐帕里布独特地改变了突变的PARP1动态,影响了癌细胞的亡和药物的疗效.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚ADP-ribose) 聚合酶1 (PARP1) 对于DNA修复至关重要,也是癌症治疗的目标.
- 这种V762A PARP1变种与癌症风险增加有关.
- 美国食品和药物管理局批准的PARP1抑制剂包括niraparib,rucaparib和talazoparib.
研究的目的:
- 研究PARP1 V762A突变对尼拉帕里布,鲁卡帕里布和塔拉佐帕里布的抑制的影响.
- 为了比较这些抑制剂对突变型与野生型 (WT) PARP1.1的结合和作用.
- 阐明突变如何影响抑制剂结合和PARP1动态.
主要方法:
- 用分子动力学模拟来分析WT和V762A突变PARP1.1的行为.
- 该研究比较了三种PARP1抑制剂的抑制下残留物波动,脊柱偏差和运动相关性.
- 评估了抑制剂和PARP1变体之间的结合自由能量.
主要成果:
- V762A突变导致了与niraparib和rucaparib的微小动态差异,但与talazoparib的显著变化.
- 塔拉佐帕里布独特地减少了突变PARP1关键催化区域的波动,但在突变部位增强了破坏稳定的相互作用.
- 塔拉佐帕里布还破坏了突变体的功能终端区域动态,与其他抑制剂不同.
- 抑制剂比WT PARP1更有效地与V762A突变体结合,具有类似的结合自由能量.
结论:
- PARP1 V762A突变对FDA批准的PARP1抑制剂,特别是talazoparib的抑制有不同的影响.
- 塔拉佐帕里布与V762A突变的独特相互作用可能会影响其在治疗与这种变异相关的癌症中的有效性.
- 了解这些突变特异性动态对于个性化癌症治疗至关重要.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mismatch Repair
4.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.7K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


